Browse CD69

Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type II membrane protein.
Domain PF00059 Lectin C-type domain
Function

Involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.

> Gene Ontology
 
Biological Process GO:0035690 cellular response to drug
GO:0042493 response to drug
Molecular Function GO:0030246 carbohydrate binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD69 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD69 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29599411melanomaPromote immunity (T cell function); increase the efficacy of immunotherapyDurable responses, however, occur in less than half of those treated, and efforts to improve treatment efficacy are confounded by a lack of understanding of the characteristics of the cells that initiate antitumor immune response.Experimental Design: We performed multiparameter flow cytometry and quantitative multiplex immunofluorescence staining on tumor specimens from immunotherapy-na?ve melanoma patients and longitudinal biopsy specimen obtained from patients undergoing anti-PD-1 therapy.Results: Increased numbers of CD69+CD103+ tumor-resident CD8+ T cells were associated with improved melanoma-specific survival in immunotherapy-na?ve melanoma patients.
24242212Colon CarcinomaPromote immunityThe anti-tumor activity could be attributed to the stimulation of immune cells with an elevated expression of the activation marker CD69 on NK, T and NKT cells and the infiltration of CD45+ immune cells into the solid tumor.
22184722Hepatocellular CarcinomaInhibit immunityIn this study, we showed that, upon encountering autologous CD69(+) T cells, tumor macrophages (MΦs) acquired the ability to produce much greater amounts of IDO protein in cancer nests. The T cells isolated from the hepatocellular carcinoma tissues expressed significantly more CD69 molecules than did those on paired circulating and nontumor-infiltrating T cells; these tumor-derived CD69(+) T cells could induce considerable IDO in monocytes.
25229656Cervical CarcinomaPromote immunity (NK cell function)Indeed, in the presence of HPV-VLPs, DCs further activated NK cells by inducing the upregulation of cell surface activation markers (CD69 and HLADR). The function of NK cells was also improved as shown by an increase in IFN-γ secretion and cytotoxic activity against an HPV+ cell line
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD69 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD69 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2560.675
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5540.65
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0410.967
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6920.279
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3180.274
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1010.946
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3920.49
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4550.631
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3290.746
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4820.622
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1540.916
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4550.0819
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD69 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD69. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD69. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD69.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD69. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD69 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD69 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD69
NameCD69 molecule
Aliases CLEC2C; CD69 antigen (p60, early T-cell activation antigen); BL-AC/P26; GP32/28; MLR-3; C-type lectin domain ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD69 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.